

Randomised controlled trial of average volume-assured pressure support (AVAPS) versus spontaneous/times (ST) mode pressure support ventilation in obesity hypoventilation syndrome

Submission date 15/09/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 11/12/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 30/11/2012	Condition category Respiratory	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims?

There is an increase worldwide in obesity and obesity related respiratory problems. In patients with severe obesity, significant breathing problems can develop which may prevent them from breathing properly during sleep. This can cause a build-up of waste gas in the blood and is called respiratory failure. Although this problem is increasingly common the best way to treat it remains unclear. The study was designed to evaluate a new medical device aimed at better controlling patients breathing during sleep in order to improve their breathing.

Who can participate?

Patients can participate in the study if they suffer with both severe obesity and respiratory failure without other underlying breathing or muscle problems.

What does the study involve?

The study involves being randomly picked to receive either standard treatment or the new device for a 3 month period. Patients will be unaware of which device they are given and will perform a number of tests to assess breathing and sleep as well as complete questionnaires to inform us as to how their condition affects their everyday lives.

What are the possible benefits and risks of participating?

It is not thought that there are any specific risks associated with the new device but taking part in the trial will involve additional trips to hospital. It is hoped that the new device may offer some improvements in symptom control and tolerability for patients.

Where is the study run from?

The lead study site is the Lane Fox Unit, St Thomas Hospital part of the Kings Academic Health Science Centre.

When is the study starting and how long is it expected to run for?
The study started in 2008 and was completed in 2010.

Who is funding the study?
Philips-Respironics

Who is the main contact?
Dr Patrick Murphy
patrickmurphy1@nhs.net

Contact information

Type(s)
Scientific

Contact name
Dr Nicholas Hart

Contact details
Lane Fox Respiratory Unit
St Thomas' Hospital
Department of Critical Care
Guy's and St Thomas' NHS Foundation Trust
Lambeth Palace Road
London
United Kingdom
SE1 7EH
nicholas.hart@gstt.nhs.uk

Additional identifiers

Protocol serial number
EAME2007AVAPS001

Study information

Scientific Title

Acronym
AVAPS-OHS

Study objectives
Average volume-assured pressure support (AVAPS) mode will deliver nocturnal ventilatory support more effectively than the spontaneous/times (S/T) mode and have greater physiological and clinical benefits in a subgroup of obesity hypoventilation syndrome (OHS) patients with severe obesity and marked daytime hypercapnia.

Ethics approval required
Old ethics approval format

Ethics approval(s)

Guys Research Ethics Committee, South London REC Office 3 gave approval on the 21st January 2008 (ref: 07/H0804/140)

Study design

Randomised parallel-group controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Obesity hypoventilation syndrome

Interventions

Bi-level positive airway pressure (BiPAP) ventilator will provide both the S/T and AVAPS modes.

Total duration of intervention/follow-up: 3 months

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Effectiveness of the nocturnal ventilatory support, assessed using the PaCO₂ - daytime arterial blood gas (ABG) at baseline and 3 months

Key secondary outcome(s)

Physiological and clinical benefits in a subgroup of OHS patients with severe obesity and marked daytime hypercapnia, assessed by the following at baseline and 3 months:

1. Partial pressure of oxygen in arterial blood (PaO₂), pH, bicarbonate areterial blood gas (HCO₃-ABG)
2. Health related quality of life: Severe Respiratory insufficiency Questionnaire, Fatigue Severity Questionnaire
3. Anthropometric data: weight, BMI, neck, hip and waist circumference
4. Activity: Actiwatch®
5. Daytime vigilance: Epworth Sleepiness Scale, Oxford Sleep Resistance (OSLER) test

Completion date

01/09/2009

Eligibility

Key inclusion criteria

1. Both males and females, aged 18 - 90 years
2. Body mass index (BMI) greater than 40 kg/m²
3. Daytime partial pressure of carbon dioxide in the arterial blood (PaCO₂) greater than 6.5 kPa

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

Forced expiratory volume in one second (FEV₁)/forced vital capacity (FVC) less than 70%

Date of first enrolment

01/09/2008

Date of final enrolment

01/09/2009

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Lane Fox Respiratory Unit

London

United Kingdom

SE1 7EH

Sponsor information**Organisation**

Respironics International, Inc. (France)

ROR

<https://ror.org/05jz46060>

Funder(s)

Funder type

Industry

Funder Name

Respironics International, Inc. (France)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2012		Yes	No